FAK down-regulation was found to potentiate rapamycin-induced suppression of ALL cell growth both in vitro and in vivo, suggesting a new concept of ALL treatment (i.e., the targeting of both mTOR- and FAK-related pathways) to achieve more powerful therapeutic effect. This evidence concerns the gene MTOR and acute lymphoblastic leukemia.